Shares of Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.07 and traded as high as $0.0920. Mateon Therapeutics shares last traded at $0.0809, with a volume of 146,837 shares changing hands.
Mateon Therapeutics Stock Up 15.9%
The company has a 50-day moving average price of $0.09 and a 200-day moving average price of $0.07. The firm has a market capitalization of $7.30 million, a price-to-earnings ratio of -4.05 and a beta of 1.33.
About Mateon Therapeutics
Mateon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies that selectively target tumor tissue. The company’s platform leverages tumor-activated peptides designed to bind to the fibrin–fibronectin complexes uniquely present in solid tumors, with the goal of improving the therapeutic index of cytotoxic payloads while limiting off-target effects.
Its lead asset, MH1, is a peptide–drug conjugate in Phase I clinical trials for advanced solid tumors.
See Also
- Five stocks we like better than Mateon Therapeutics
- Wall Street Alert: Buy AES
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Bitcoin is down but your income is about to explode
- A month before the crash
- Trump Devises the Death of the IRS ☠️
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
